Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Zymeworks, Inc. is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are spread across 4 distinct examiners, indicating that each examiner is responsible for a pending matter. This spread across 4 distinct examiners suggests that the company's prosecution is not concentrated under a single individual's review style. Furthermore, the 4 pending office actions are located in 4 distinct art units, reflecting a high degree of technical variety within the biotechnology sector.
HUYNH, PHUONG N is identified as the busiest examiner, currently holding 1 pending office action. This matches the workload of the other distinct examiners. With 4 distinct art units involved, the company must navigate 4 different sets of technical standards and prior art landscapes. Practitioners should be prepared for varied examiner styles, as the 4 pending office actions are entirely decentralized across both personnel and art units. This diversity requires a highly individualized approach for each pending matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
| 17624541 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | MIDDLETON, DANAYA L | 6d |
| 18551851 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | HOLTZMAN, KATHERINE ANN | — |
| 17999477 | IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 1641 | §102§112 | Final Rejection | 238d overdue | Pending | Mar 21, 2024 |
| 18551851 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | HOLTZMAN, KATHERINE ANN | 1646 | §112DP | Final Rejection | — | Pending | Sep 21, 2023 |
| 17999477 | IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17624541 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | MIDDLETON, DANAYA L | 1674 | §112Other | Final Rejection | 6d | Pending | Jan 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial